European fund opportunities: monetary and fiscal stimulus supports JEDT’s outperformance

JEDT

JPMorgan European Discovery Trust plc (LON:JEDT) has released its latest factsheet.

Month in review as of 31/01/2026

  • The trust outperformed the benchmark over January.
  • At the stock level, our overweight position in Danieli, one of the largest suppliers of plants and equipment to the metals industry, contributed to performance given continued strong order momentum.
  • Our overweight position in Kitron, a leading electronic manufacturing services (EMS) provider also contributed to performance due to a positive defence exposure and outlook, as well as the closing of a notable acquisition.
  • Our overweight position in Unipol, a leading Italian insurance company, detracted from performance due to general weakness across the insurance sector, as well as concerns over self-driving vehicles reducing demand for motor insurance over the longer-term.
  • Our overweight position in Temenos, a banking software provider, also detracted from performance due to general negative sentiment towards software companies given the disruptive threat of AI.

Looking ahead as of 31/01/2026

  • Europe has been and should continue to be a beneficiary of monetary stimulus. The eurozone is still an economy sensitive to short-term interest rates, and past rate cuts continue to support credit growth.
  • Fiscal stimulus has also contributed to the strong performance of southern Europe, which has benefited significantly from the EU’s Recovery Fund.
Share on:

Latest Company News

Drax targets a bigger role as Britain reshapes its power system

Britain needs more than renewable generation to reshape its power system, and Drax is developing generation, storage and flexibility assets to address that need.

Valeura Energy features in 2026 TSX 30 as energy and commodities drive market interest

Valeura Energy’s inclusion in the 2026 TSX 30 highlights its position within a market increasingly focused on energy security, commodity supply and international production.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Touchstone Exploration moves ahead with Trinidad drilling and production plans

Touchstone Exploration is advancing drilling, well work and production optimisation across Trinidad, with several key operational results expected during the rest of 2026.

Ilika targets Europe’s next phase of solid-state battery development

Ilika is positioned around Europe’s push for next-generation solid-state batteries as manufacturers seek better performance and less dependence on Asian supply chains.

Pantheon International reports 3.2% NAV growth in Q3 2026

Pantheon International’s NAV per share rose 3.2% to 534.6p in the quarter ended 31 August 2026, alongside £130.9m of new investment commitments.

    Search